Abstract
Online hemodiafiltration (HDF) has received significant attention as a potentially superior dialysis modality compared to conventional high-flux hemodialysis for patients with end-stage kidney disease. The CONVINCE (CONvective VERSus diffusive dialysis in patients with End-stage kidney disease) trial, subsequent meta-analyses, and observational studies indicate that high-dose HDF (≥23 L convection per session) is associated with improved survival outcomes, particularly through reductions in cardiovascular and possibly also infection-related mortality. Additionally, emerging evidence suggests modest but meaningful benefits in health-related quality of life and symptom control. This comment synthesizes the current literature (2022-2025), highlighting clinical outcomes, patient-centered metrics, feasibility, cost-effectiveness, personalized treatment considerations, and implications for clinical practice. Additionally, practical prescription guidance is provided to assist nephrologists in achieving optimal convection volumes and clinical outcomes in routine clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 875-879 |
| Number of pages | 5 |
| Journal | Kidney research and clinical practice |
| Volume | 44 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Nov 2025 |
Keywords
- Clinical trial
- Hemodiafiltration
- Hemodialysis
- Mortality
Fingerprint
Dive into the research topics of 'High-volume online hemodiafiltration versus high-flux hemodialysis: a short review of recent evidence and a discussion on clinical implementation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver